Hepatitis/MASH

Regimen of sofosbuvir/velpatasvir/voxilaprevir treats hepatitis C virus genotypes 1 to 6.

Conflicts of interest among committee members who set hepatitis C treatment guidelines may influence decision-making.

Worldwide there are more than 350,000 HCV-related deaths per year.

Quest Diagnostics launches a test that determines patient response to costly hepatitis B virus drugs.

Patient with a failing liver who received an HCV-infected liver cured of the virus.

Cognitive impairment more prevalent in patients with HIV coinfection than in those with hepatitis C infection alone.

Successful treatment with buprenorphine is crucial for patients with opioid use disorder.

Glecaprevir is a NS3/4A protease inhibitor and pibrentasvir is a NS5A inhibitor for hepatitis C patients without cirrhosis.

Glecaprevir/pibrentasvir is indicated as an eight-week treatment for hepatitis C among patients without cirrhosis.

Company seeks to leverage technologies to address unmet needs.

Top news of the day from across the health care landscape.

This fixed-dose combination of sofosbuvir and velpatasvir is indicated to treat chronic HCV genotypes 1-6.

Novartis partners with Conatus to develop a new drug for non-alcoholic steatohepatitis.

Hepatitis A infection rates have decreased in the United States and are the lowest they have been in 40 years.

Combination drugs may cause adverse events in individuals coinfected with HIV and HCV.

Top articles of 2016 on Specialty Pharmacy Times.

Top HCV articles of the year on Specialty Pharmacy Times.

Study seeks the optimal drug combination for patients with HCV genotype 2 and cirrhosis.

Reovirus could treat liver diseases such as hepatitis C virus and primary liver cancer.

Over the years, a number of landmark clinical studies in virology have been published, shaping how we treat the disease today.

HCV patients without cirrhosis achieved SVR after 8 weeks of treatment with glecaprevir/pibrentasvir.

HCV patients without cirrhosis achieved SVR after 8 weeks of treatment with glecaprevir/pibrentasvir.

After 2 years of exclusion, Harvoni has been added to the Express Scripts national formulary for the treatment of hepatitis C.

The state’s health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

Agreement will expand treatment options for patients with hepatitis C.